Thursday, January 29, 2009
THURSDAY, Jan. 29 (HealthDay News) -- A measles virus strain engineered to express the human carcinoembryonic antigen shows promise in the treatment of prostate cancer, according to research published in the January issue of The Prostate.
Pavlos Msaouel, M.D., of the Mayo Clinic in Rochester, Minn., and colleagues tested the virus in the Vero (African green monkey) cell line and human prostate cancer cell lines PC-3, DU-145, and LNCaP. They also tested the virus in mice that received subcutaneous injections of prostate cancer cells.
During the in vitro experiments, the investigators found that the virus effectively infected, replicated in and killed prostate cancer cells. The researchers also found that the survival time was almost doubled in treated mice compared to control mice, and observed complete tumor regression in 20 percent of the treated animals.
"The finding of measles virus-carcinoembryonic antigen efficacy against prostate cancer irrespective of androgen-sensitivity supports the therapeutic promise of recombinant measles virotherapy in diverse populations of prostate cancer tumors," the authors conclude. "Our results set the foundation for additional studies in preparation for using engineered measles strains in a clinical trial for the treatment of prostate cancer."
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.